Revvity’s Dharmacon™ CRISPR portfolio expands with validated CRISPR guide RNAs for complex but critical gene targets, as well as DNA cutting controls for screen normalization in sensitive assays.
9 result(s)
With the requirement of thorough in vitro assays and high throughput screening technologies to ensure drug safety and efficacy, make sure you're fully ready for when you submit your IND application by assessing immunogenicity with an MLR assay
Learn about how T cell exhaustion poses a significant challenge in immuno-oncology and the way epigenetic mechanisms can help develop strategies for reinvigorating exhausted T cells.
Accell siRNAは、トランスフェクションが困難な初代免疫細胞の遺伝子ノックアウトに使用されており、多くの参考文献があります。詳細については、こちらをご覧ください。
ヒト細胞モデルを研究に組み込む必要があってもどこから始めればよいかわからないことがありますか？モデルシステムとしてのiPS細胞の使用は、賢い開始点です。
Can base editing move cancer cell therapy further towards off-the-shelf treatments?
Demonstration of a repeatable pooled lentiviral sgRNA screen in primary human T cells
Gene editing by CRISPR has led to significant advances in immunotherapy development. Here we offer several tips for successful editing in T cells, including recommendations for cell handling, nucleofection, and analysis.
Achieve DNA-free guaranteed gene editing with synthetic predesigned sgRNA reagents and libraries covering the entire human genome.